ClinicalTrials.gg
CompletedNCT07138378XS003-11Updated Aug 22, 2025

A Bioavailability Study of Nilotinib in Healthy, Adult, Human Subjects Under Fasted Conditions.

A Phase 1 interventional study of XS003 (nilotinib) and Tasigna (nilotinib) in Cancer, sponsored by Xspray Pharma AB. Completed at 1 site in India. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-22.

Sponsored by Xspray Pharma AB · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Nov 2024, registered Jul 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

An open label, single-center, balanced, randomized, four-treatment, four-sequence, four-period, single dose, crossover, comparative bioavailability study in healthy, adult, human subjects under fasteding conditions

Read the detailed description

To evaluate the relative bioavailability of XS003 capsules 2x48mg (96mg) versus Tasigna 200 mg, and XS003 capsules 4x48mg versus Tasigna 400 mg after a single dose under fasted conditions in healthy, adult, human subjects.

02

Conditions studied

  • Cancer

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 128 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Xspray Pharma AB is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A willing study participant to become eligible for the study must fulfill all of the below inclusion criteria:

  • Healthy, human beings 18 and 45 years of age (both inclusive).
  • Subjects weighing at least 50 kg, having a between 18.5 Kg/m2 and 29.9 Kg/m2 (both inclusive).
  • Subject must be able to provide written with a detailed description of nature of the drug.
  • Acceptable medical history, physical examination, , laboratory investigations within 21 days prior to enrollment and chest X-ray (Valid for 180 days).
  • Female subjects must meet one of the following criteria:

    • Physiological status, defined as the following.
    • Absence of menses for at least one year prior to the first study drug administration (without an alternative medical condition); and
    • FSH levels ≥40 mlU/mL at screening or
    • Surgical postmenopausal status, defined as the following.
    • Bilateral Oophorectomy and
    • Absence of menses for at least 90 days prior to the screening or
    • Post hysterectomy status
    • If postmenopausal and has an FSH of \< 40 mlU/mL, but meets all other criteria in (i), (ii) or (iii) above as well as all the other inclusion criteria, screening estradiol serum level must be ≤ 150 pmol/L.

or

  • iv.Surgically rendered non- by bilateral tubal ligation
  • Must agree to use an adequate method of . Subjects who are sexually active must use, with their partner, a condom AND one of the following methods of highly effective contraception from the time of IMP administration until 90 days after the last dose of IMP
  • oral (except low-doselow dose gestagen (lynestrenol and norestisteron)), injectable or implanted hormonal contraceptives
  • intrauterine device or system (e.g., progestin-releasing coil)
  • vasectomized male (with appropriate post vasectomy documentation of the absence of sperm in the ejaculate)
  • bilateral tubal occlusion or hysterectomy

    • Clinical laboratory values should be within the laboratory's stated normal range. If not within this range, they must be without clinical significance, as determined by the Investigator.
    • The subject is able to communicate meaningfully with study personnel and is anticipated to be able to comply fully with study procedures and must be willing and able to communicate and participate in the whole study.
    • Male subjects should not donate sperm during the study and for 90 days after the last administration of IMP.
    • Non-smokers .

Exclusion criteria

Exclusion Criteria:

A willing study participant will be excluded from the study, if any of the below criteria is met:

  • Systolic blood pressure less than 100 mm of Hg or more than 140 mm of Hg.
  • Diastolic blood pressure less than 60 mm of Hg or more than 90 mm of Hg.
  • Note: If vital signs are out-of-range, the investigator may obtain one additional reading so that up to 2 consecutive assessments are made within 1.00 hour with the subject seated quietly during the 5 minutes preceding the assessment.
  • Body temperature less than 95.0 °F (35.0 °C) or more than 98.6°F (37.0°C).
  • Radial Pulse rate less than 60/min or more than 100/min.
  • History of or idiosyncratic reaction to drug product or any other related drugs.
  • History of , cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological, or psychiatric disease or disorder.
  • Taken drugs that are substrates or inhibitors of P-glycoproteins in last 30 days prior to the check-in (see Appendix-5).
  • History of hematological, malignant, and bleeding disorders.
  • On anticoagulant therapy.
  • History of hypokalemia, hypomagnesemia, or a history of cardiac disease.
  • History of cholecystectomy or gall stones.
  • History of any drug or alcohol abuse in the past 2 years.
  • History of intake of strong inhibitors (see Appendix-5) or inducers within
  • 4 weeks prior to the check-in.
  • History of intake of drugs known to prolong the within 4 weeks prior to the check-in
  • History of rare hereditary problems of galactose intolerance, severe lactase deficiency with a severe degree of intolerance to lactose-containing products, or of glucose-galactose malabsorption.
  • A prolonged QTc interval (QTc greater than 450 msec demonstrated on at Screening.
  • Any ECG abnormalities that, in the Investigator's opinion, would compromise the subject's safety.
  • Regular alcohol consumption in males >21 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type).
  • History or family history of long QT syndrome.
  • Significant history or current evidence of risk factors for Torsade de Pointes (TdP).
  • History of Gilbert syndrome.
  • A history of difficulty with donating blood and having poor vein access.
  • Male subjects with pregnant or lactating partners.
  • Taking, or have taken, any prescribed or over-the-counter drug or herbal remedies, vitamins, or minerals and intake of any medication except caffeine, ranitidine, paracetamol, diclofenac sodium and ondansetron in the 30 days before check-in (other than up to 4 gr of paracetamol per day).
  • Consumption of the xanthine containing food or beverages (like tea, coffee, chocolates, and flavored drinks) at least 48 hours before check-in of each period.
  • Consumption of the grapefruit or grapefruit juice, pomegranate, or pomegranate juice, pomelo, starfruit, Seville oranges and St. John's Wort at least 14 days before check-in of each period.
  • Consumption of tobacco containing products (including smoking cigarettes or chewing tobacco products), e-cigarettes and/or nicotine replacement products within 3 months prior to the check-in.
  • Consumption of all kinds of alcoholic beverages from at least 48.00 hours prior to check-in.
  • Difficulty in abstaining from all kinds of alcoholic beverages during entire study period.
  • Difficulty in abstaining from the xanthine containing food or beverages (like tea, coffee, chocolates, and flavored drinks), grapefruit or grapefruit juice, pomelo, pomegranate, or pomegranate juice, pomelo, starfruit, Seville oranges and St. John's Wort during entire study period.
  • Difficulty in abstaining from the smoking or chewing tobacco products during entire study period.
  • Confirmed positive for drugs of abuse (benzodiazepines, tetrahydrocannabinol, amphetamine, cocaine, barbiturates, and morphine) on check-in of any period.
  • Confirmed positive alcohol (breath) test on check-in of any period.
  • Confirmed positive urine cotinine test on check-in of any period.
  • Participated in any other clinical study or donated blood in last 90 days.
  • Positive screens for serum surface antigen (HbsAg), antibody (HepC) or (HIV).
  • Participated in contact sports or unaccustomed strenuous exercise in the 72 hours before check-in of any period.
  • History of clinically significant allergy.
  • History of allergy or sensitivity to nilotinib, or history of any food or drug hypersensitivity or intolerance which, in the opinion of the Investigator, would compromise the safety of the subject or the study.
  • Significant history or current evidence of chronic infectious disease, system disorders, organ dysfunction especially cardiovascular disorders (e.g., arterial vascular occlusive events), respiratory disorders, renal or hepatic disorders, diabetes, or obesity.
  • Greater than the values of Alkaline phosphatase (ALP), (ALT), aspartate aminotransferase (AST) and total .
  • Estimated (eGFR) \< 90 mL/min/1.73 m2 at period-1
  • check-in.
  • Clinically significant hypokalemia, hypomagnesemia, or other electrolyte disorders.
  • Clinically significant history or presence of gastrointestinal disease or history of malabsorption within the last year, as determined by the Investigator.
  • Females who are pregnant, lactating, or likely to become pregnant during the study.
  • Confirmed positive pregnancy test (for females) on check-in of any period.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
128 participants (actual)

Study arms

  • Active comparator
    Tasigna 200 mg

    A single oral dose of Treatment Tasigna 200 mg

    Drug: XS003 (nilotinib) · Drug: Tasigna (nilotinib)

  • Active comparator
    Tasigna 400 mg

    A single oral dose of Treatment Tasigna 400 mg

    Drug: XS003 (nilotinib) · Drug: Tasigna (nilotinib)

  • Experimental
    XS003 (nilotinib) 96mg

    A single oral dose of Treatment XS003 Capsules 2x48mg (96mg)

    Drug: XS003 (nilotinib) · Drug: Tasigna (nilotinib)

  • Experimental
    XS003 (nilotinib) 192mg

    A single oral dose of Treatment XS003 Capsules 4x48mg (192mg)

    Drug: XS003 (nilotinib) · Drug: Tasigna (nilotinib)

Interventions

  • To evaluate the PK dose proportionality of Tasigna 200 mg versus Tasigna 400 mg and XS003 capsules 2x48mg (96mg) versus XS003 capsules 4x48mg (192mg).

  • To evaluate the PK dose proportionality of Tasigna 200 mg versus Tasigna 400 mg and XS003 capsules 2x48mg (96mg) versus XS003 capsules 4x48mg (192mg).

06

What researchers measure

Primary outcomes

  1. Bioavailability (Peak Plasma Concentration (Cmax)) of XS003 versus Tasigna treatment

    To evaluate the relative bioavailability (Peak Plasma Concentration (Cmax)) of XS003 capsules 2x48mg (96mg) versus Tasigna 200 mg, and XS003 capsules 4x48mg versus Tasigna 400 mg after a single dose under fasted conditions in healthy, adult, human subjects.

    Time frame: PK samples will be collected at pre-dose (0.00) and between 0.50 and 120.00 hours post dose

  2. Bioavailability (Area under the plasma concentration versus time curve (AUC)) of XS003 versus Tasigna treatment

    To evaluate the relative bioavailability (Area under the plasma concentration versus time curve (AUC)) of XS003 capsules 2x48mg (96mg) versus Tasigna 200 mg, and XS003 capsules 4x48mg versus Tasigna 400 mg after a single dose under fasted conditions in healthy, adult, human subjects.

    Time frame: PK samples will be collected at pre-dose (0.00) and between 0.50 and 120.00 hours post dose

Secondary outcomes

  1. Safety (adverse events (AE)) of XS003 versus Tasigna treatment

    To evaluate the safety and tolerability (adverse events (AE, i.e treatment and non-treatment related adverse events as assessed by CTCAE v4.0)) of Tasigna 200 mg, Tasigna 400 mg, XS003 Capsules 2x48mg (96mg) and 4x48mg (192mg) in healthy, adult, human subjects under fasted conditions.

    Time frame: From baseline up to 58 days

  2. Safety (electrokardiografi ECG)) of XS003 versus Tasigna treatment

    To evaluate the safety and tolerability (electrokardiografi ECG QT Interval)) of Tasigna 200 mg, Tasigna 400 mg, XS003 Capsules 2x48mg (96mg) and 4x48mg (192mg) in healthy, adult, human subjects under fasted conditions

    Time frame: From baseline up to 58 days

07

Study locations

1 site
  • QPS Bioserve India Pvt Limited
    Hyderabad, 500037, India
08

References and documents

Individual participant data

Plan to share: No — N/A as this is a Bioavailibility study

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Dec 2024, 1 month.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 1 month is below that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2025
First posted
Aug 22, 2025
StartActual
Nov 15, 2024
Primary completionActual
Dec 15, 2024
CompletionActual
Dec 15, 2024
Last update
Aug 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07138378
Lead sponsor
Xspray Pharma AB
Responsible party
Sponsor
First posted
Aug 22, 2025
Start date
Nov 15, 2024
Primary completion
Dec 15, 2024
Completion
Dec 15, 2024
Last update
Aug 22, 2025

Study contacts

Maria Klockare
study director · Xspray Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion